EMEA-001776-PIP03-17

Key facts

Active substance
Risankizumab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0230/2018
PIP number
EMEA-001776-PIP03-17
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Solution for injection
  • Age-appropriate dosage form for parenteral use
Condition(s) / indication(s)
Treatment of Crohn's disease
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44 1628925033

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating